Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2012

01.10.2012 | Preclinical Study

Diagnostic values of GHSR DNA methylation pattern in breast cancer

verfasst von: Sandeep Kumar Botla, Amin Moghaddas Gholami, Mahdi Malekpour, Evgeny A. Moskalev, Mahdi Fallah, Pouria Jandaghi, Ali Aghajani, Irina S. Bondar, Ramesh Omranipour, Fatemeh Malekpour, Abbas Mohajeri, Azin Jahangiri Babadi, Özgür Sahin, Vladimir V. Bubnov, Hossein Najmabadi, Jörg D. Hoheisel, Yasser Riazalhosseini

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

DNA methylation patterns have been recognised as cancer-specific markers with high potential for clinical applications. We aimed at identifying methylation variations that differentiate between breast cancers and other breast tissue entities to establish a signature for diagnosis. Candidate genomic loci were analysed in 117 fresh-frozen breast specimens, which included cancer, benign and normal breast tissues from patients as well as material from healthy individuals. A cancer-specific DNA methylation signature was identified by microarray analysis in a test set of samples (n = 52, p < 2.1 × 10−4) and its performance was assessed through bisulphite pyrosequencing in an independent validation set (n = 65, p < 1.9 × 10−7). The signature is associated with SFRP2 and GHSR genes, and exhibited significant hypermethylation in cancers. Normal-appearing breast tissues from cancer patients were also methylated at these loci but to a markedly lower extent. This occurrence of methylated DNA in normal breast tissue of cancer patients is indicative of an epigenetic field defect. Concerning diagnosis, receiver operating characteristic curves and the corresponding area under the curve (AUC) analysis demonstrated a very high sensitivity and specificity of 89.3 and 100 %, respectively, for the GHSR methylation pattern (AUC >0.99). To date, this represents the DNA methylation marker of the highest sensitivity and specificity for breast cancer diagnosis. Functionally, ectopic expression of GHSR in a cell line model reduced breast cancer cell invasion without affecting cell viability upon stimulation of cells with ghrelin. Our data suggest a link between epigenetic down-regulation of GHSR and breast cancer cell invasion.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Dua RS, Isacke CM, Gui GP (2006) The intraductal approach to breast cancer biomarker discovery. J Clin Oncol 24(7):1209–1216PubMedCrossRef Dua RS, Isacke CM, Gui GP (2006) The intraductal approach to breast cancer biomarker discovery. J Clin Oncol 24(7):1209–1216PubMedCrossRef
2.
Zurück zum Zitat Andre F, Michiels S, Dessen P, Scott V, Suciu V, Uzan C, Lazar V, Lacroix L, Vassal G, Spielmann M, Vielh P, Delaloge S (2009) Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncol 10(4):381–390PubMedCrossRef Andre F, Michiels S, Dessen P, Scott V, Suciu V, Uzan C, Lazar V, Lacroix L, Vassal G, Spielmann M, Vielh P, Delaloge S (2009) Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncol 10(4):381–390PubMedCrossRef
3.
Zurück zum Zitat Brena RM, Plass C, Costello JF (2006) Mining methylation for early detection of common cancers. PLoS Med 3(12):e479PubMedCrossRef Brena RM, Plass C, Costello JF (2006) Mining methylation for early detection of common cancers. PLoS Med 3(12):e479PubMedCrossRef
4.
Zurück zum Zitat Jones PA, Takai D (2001) The role of DNA methylation in mammalian epigenetics. Science 293(5532):1068–1070PubMedCrossRef Jones PA, Takai D (2001) The role of DNA methylation in mammalian epigenetics. Science 293(5532):1068–1070PubMedCrossRef
6.
Zurück zum Zitat Vargo-Gogola T, Rosen JM (2007) Modelling breast cancer: one size does not fit all. Nat Rev Cancer 7(9):659–672PubMedCrossRef Vargo-Gogola T, Rosen JM (2007) Modelling breast cancer: one size does not fit all. Nat Rev Cancer 7(9):659–672PubMedCrossRef
7.
Zurück zum Zitat Gal-Yam EN, Saito Y, Egger G, Jones PA (2008) Cancer epigenetics: modifications, screening, and therapy. Annu Rev Med 59:267–280PubMedCrossRef Gal-Yam EN, Saito Y, Egger G, Jones PA (2008) Cancer epigenetics: modifications, screening, and therapy. Annu Rev Med 59:267–280PubMedCrossRef
9.
Zurück zum Zitat Veeck J, Ropero S, Setien F, Gonzalez-Suarez E, Osorio A, Benitez J, Herman JG, Esteller M (2010) BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol 28(29):e563–e564 author reply e565–566PubMedCrossRef Veeck J, Ropero S, Setien F, Gonzalez-Suarez E, Osorio A, Benitez J, Herman JG, Esteller M (2010) BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol 28(29):e563–e564 author reply e565–566PubMedCrossRef
10.
Zurück zum Zitat Zhang Y, Rohde C, Tierling S, Jurkowski TP, Bock C, Santacruz D, Ragozin S, Reinhardt R, Groth M, Walter J, Jeltsch A (2009) DNA methylation analysis of chromosome 21 gene promoters at single base pair and single allele resolution. PLoS Genet 5(3):e1000438PubMedCrossRef Zhang Y, Rohde C, Tierling S, Jurkowski TP, Bock C, Santacruz D, Ragozin S, Reinhardt R, Groth M, Walter J, Jeltsch A (2009) DNA methylation analysis of chromosome 21 gene promoters at single base pair and single allele resolution. PLoS Genet 5(3):e1000438PubMedCrossRef
11.
Zurück zum Zitat Hoheisel JD (2006) Microarray technology: beyond transcript profiling and genotype analysis. Nat Rev Genet 7(3):200–210PubMedCrossRef Hoheisel JD (2006) Microarray technology: beyond transcript profiling and genotype analysis. Nat Rev Genet 7(3):200–210PubMedCrossRef
12.
Zurück zum Zitat Riazalhosseini Y, Hoheisel J (2008) Do we use the appropriate controls for the identification of informative methylation markers for early cancer detection? Genome Biol 9(11):405PubMedCrossRef Riazalhosseini Y, Hoheisel J (2008) Do we use the appropriate controls for the identification of informative methylation markers for early cancer detection? Genome Biol 9(11):405PubMedCrossRef
13.
Zurück zum Zitat Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5(10):R80PubMedCrossRef Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5(10):R80PubMedCrossRef
14.
Zurück zum Zitat Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3:Article3 Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3:Article3
15.
Zurück zum Zitat Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc 57(1):289–300 Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc 57(1):289–300
16.
Zurück zum Zitat Fellenberg K, Hauser NC, Brors B, Neutzner A, Hoheisel JD, Vingron M (2001) Correspondence analysis applied to microarray data. Proc Natl Acad Sci USA 98(19):10781–10786PubMedCrossRef Fellenberg K, Hauser NC, Brors B, Neutzner A, Hoheisel JD, Vingron M (2001) Correspondence analysis applied to microarray data. Proc Natl Acad Sci USA 98(19):10781–10786PubMedCrossRef
17.
Zurück zum Zitat Moskalev EA, Zavgorodnij MG, Majorova SP, Vorobjev IA, Jandaghi P, Bure IV, Hoheisel JD (2011) Correction of PCR-bias in quantitative DNA methylation studies by means of cubic polynomial regression. Nucleic Acids Res 39(11):e77PubMedCrossRef Moskalev EA, Zavgorodnij MG, Majorova SP, Vorobjev IA, Jandaghi P, Bure IV, Hoheisel JD (2011) Correction of PCR-bias in quantitative DNA methylation studies by means of cubic polynomial regression. Nucleic Acids Res 39(11):e77PubMedCrossRef
18.
Zurück zum Zitat Perez RP, Hamilton TC, Ozols RF, Young RC (1993) Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer 71(4 Suppl):1571–1580PubMedCrossRef Perez RP, Hamilton TC, Ozols RF, Young RC (1993) Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer 71(4 Suppl):1571–1580PubMedCrossRef
19.
Zurück zum Zitat Ordway JM, Budiman MA, Korshunova Y, Maloney RK, Bedell JA, Citek RW, Bacher B, Peterson S, Rohlfing T, Hall J, Brown R, Lakey N, Doerge RW, Martienssen RA, Leon J, McPherson JD, Jeddeloh JA (2007) Identification of novel high-frequency DNA methylation changes in breast cancer. PLoS ONE 2(12):e1314PubMedCrossRef Ordway JM, Budiman MA, Korshunova Y, Maloney RK, Bedell JA, Citek RW, Bacher B, Peterson S, Rohlfing T, Hall J, Brown R, Lakey N, Doerge RW, Martienssen RA, Leon J, McPherson JD, Jeddeloh JA (2007) Identification of novel high-frequency DNA methylation changes in breast cancer. PLoS ONE 2(12):e1314PubMedCrossRef
20.
Zurück zum Zitat Huang TH, Perry MR, Laux DE (1999) Methylation profiling of CpG islands in human breast cancer cells. Hum Mol Genet 8(3):459–470PubMedCrossRef Huang TH, Perry MR, Laux DE (1999) Methylation profiling of CpG islands in human breast cancer cells. Hum Mol Genet 8(3):459–470PubMedCrossRef
21.
Zurück zum Zitat Euhus DM, Bu D, Milchgrub S, Xie X-J, Bian A, Leitch AM, Lewis CM (2008) DNA methylation in benign breast epithelium in relation to age and breast cancer risk. Cancer Epidemiol Biomark Prev 17(5):1051–1059CrossRef Euhus DM, Bu D, Milchgrub S, Xie X-J, Bian A, Leitch AM, Lewis CM (2008) DNA methylation in benign breast epithelium in relation to age and breast cancer risk. Cancer Epidemiol Biomark Prev 17(5):1051–1059CrossRef
22.
Zurück zum Zitat Lewis CM, Cler LR, Bu DW, Zochbauer-Muller S, Milchgrub S, Naftalis EZ, Leitch AM, Minna JD, Euhus DM (2005) Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res 11(1):166–172PubMed Lewis CM, Cler LR, Bu DW, Zochbauer-Muller S, Milchgrub S, Naftalis EZ, Leitch AM, Minna JD, Euhus DM (2005) Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res 11(1):166–172PubMed
23.
Zurück zum Zitat Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Weisenberger DJ, Shen H, Campan M, Noushmehr H, Bell CG, Maxwell AP, Savage DA, Mueller-Holzner E, Marth C, Kocjan G, Gayther SA, Jones A, Beck S, Wagner W, Laird PW, Jacobs IJ, Widschwendter M (2010) Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res 20(4):440–446PubMedCrossRef Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Weisenberger DJ, Shen H, Campan M, Noushmehr H, Bell CG, Maxwell AP, Savage DA, Mueller-Holzner E, Marth C, Kocjan G, Gayther SA, Jones A, Beck S, Wagner W, Laird PW, Jacobs IJ, Widschwendter M (2010) Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res 20(4):440–446PubMedCrossRef
24.
Zurück zum Zitat Yan PS, Venkataramu C, Ibrahim A, Liu JC, Shen RZ, Diaz NM, Centeno B, Weber F, Leu Y-W, Shapiro CL, Eng C, Yeatman TJ, Huang THM (2006) Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res 12(22):6626–6636PubMedCrossRef Yan PS, Venkataramu C, Ibrahim A, Liu JC, Shen RZ, Diaz NM, Centeno B, Weber F, Leu Y-W, Shapiro CL, Eng C, Yeatman TJ, Huang THM (2006) Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res 12(22):6626–6636PubMedCrossRef
25.
Zurück zum Zitat Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH (2003) A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res 63(8):1727–1730PubMed Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH (2003) A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res 63(8):1727–1730PubMed
26.
Zurück zum Zitat Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, Vilaythong J, Houlihan PS, Krouse RS, Prasad AR, Einspahr JG, Buckmeier J, Alberts DS, Hamilton SR, Issa JP (2005) MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 97(18):1330–1338PubMedCrossRef Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, Vilaythong J, Houlihan PS, Krouse RS, Prasad AR, Einspahr JG, Buckmeier J, Alberts DS, Hamilton SR, Issa JP (2005) MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 97(18):1330–1338PubMedCrossRef
27.
Zurück zum Zitat Wang LS, Arnold M, Huang YW, Sardo C, Seguin C, Martin E, Huang TH, Riedl K, Schwartz S, Frankel W, Pearl D, Xu Y, Winston J 3rd, Yang GY, Stoner G (2011) Modulation of genetic and epigenetic biomarkers of colorectal cancer in humans by black raspberries: a phase I pilot study. Clin Cancer Res 17(3):598–610PubMedCrossRef Wang LS, Arnold M, Huang YW, Sardo C, Seguin C, Martin E, Huang TH, Riedl K, Schwartz S, Frankel W, Pearl D, Xu Y, Winston J 3rd, Yang GY, Stoner G (2011) Modulation of genetic and epigenetic biomarkers of colorectal cancer in humans by black raspberries: a phase I pilot study. Clin Cancer Res 17(3):598–610PubMedCrossRef
28.
Zurück zum Zitat Wolff EM, Chihara Y, Pan F, Weisenberger DJ, Siegmund KD, Sugano K, Kawashima K, Laird PW, Jones PA, Liang G (2010) Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res 70(20):8169–8178PubMedCrossRef Wolff EM, Chihara Y, Pan F, Weisenberger DJ, Siegmund KD, Sugano K, Kawashima K, Laird PW, Jones PA, Liang G (2010) Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res 70(20):8169–8178PubMedCrossRef
29.
Zurück zum Zitat Hill VK, Ricketts C, Bieche I, Vacher S, Gentle D, Lewis C, Maher ER, Latif F (2011) Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res 71(8):2988–2999PubMedCrossRef Hill VK, Ricketts C, Bieche I, Vacher S, Gentle D, Lewis C, Maher ER, Latif F (2011) Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res 71(8):2988–2999PubMedCrossRef
30.
Zurück zum Zitat Bailey VJ, Zhang Y, Keeley BP, Yin C, Pelosky KL, Brock M, Baylin SB, Herman JG, Wang TH (2010) Single-tube analysis of DNA methylation with silica superparamagnetic beads. Clin Chem 56(6):1022–1025PubMedCrossRef Bailey VJ, Zhang Y, Keeley BP, Yin C, Pelosky KL, Brock M, Baylin SB, Herman JG, Wang TH (2010) Single-tube analysis of DNA methylation with silica superparamagnetic beads. Clin Chem 56(6):1022–1025PubMedCrossRef
31.
Zurück zum Zitat Evron E, Dooley WC, Umbricht CB, Rosenthal D, Sacchi N, Gabrielson E, Soito AB, Hung DT, Ljung B, Davidson NE, Sukumar S (2001) Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 357(9265):1335–1336PubMedCrossRef Evron E, Dooley WC, Umbricht CB, Rosenthal D, Sacchi N, Gabrielson E, Soito AB, Hung DT, Ljung B, Davidson NE, Sukumar S (2001) Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 357(9265):1335–1336PubMedCrossRef
32.
Zurück zum Zitat Fackler MJ, Malone K, Zhang Z, Schilling E, Garrett-Mayer E, Swift-Scanlan T, Lange J, Nayar R, Davidson NE, Khan SA, Sukumar S (2006) Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res 12(11 Pt 1):3306–3310PubMedCrossRef Fackler MJ, Malone K, Zhang Z, Schilling E, Garrett-Mayer E, Swift-Scanlan T, Lange J, Nayar R, Davidson NE, Khan SA, Sukumar S (2006) Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res 12(11 Pt 1):3306–3310PubMedCrossRef
33.
Zurück zum Zitat Suijkerbuijk KP, van der Wall E, Meijrink H, Pan X, Borel Rinkes IH, Ausems MG, van Diest PJ (2010) Successful oxytocin-assisted nipple aspiration in women at increased risk for breast cancer. Fam Cancer 9(3):321–325PubMedCrossRef Suijkerbuijk KP, van der Wall E, Meijrink H, Pan X, Borel Rinkes IH, Ausems MG, van Diest PJ (2010) Successful oxytocin-assisted nipple aspiration in women at increased risk for breast cancer. Fam Cancer 9(3):321–325PubMedCrossRef
34.
Zurück zum Zitat Komenaka IK, Ditkoff BA, Joseph KA, Russo D, Gorroochurn P, Ward M, Horowitz E, El-Tamer MB, Schnabel FR (2004) The development of interval breast malignancies in patients with BRCA mutations. Cancer 100(10):2079–2083PubMedCrossRef Komenaka IK, Ditkoff BA, Joseph KA, Russo D, Gorroochurn P, Ward M, Horowitz E, El-Tamer MB, Schnabel FR (2004) The development of interval breast malignancies in patients with BRCA mutations. Cancer 100(10):2079–2083PubMedCrossRef
35.
Zurück zum Zitat Suijkerbuijk KP, van Diest PJ, van der Wall E (2011) Improving early breast cancer detection: focus on methylation. Ann Oncol 22(1):24–29PubMedCrossRef Suijkerbuijk KP, van Diest PJ, van der Wall E (2011) Improving early breast cancer detection: focus on methylation. Ann Oncol 22(1):24–29PubMedCrossRef
36.
Zurück zum Zitat Lieske B, Ravichandran D, Wright D (2006) Role of fine-needle aspiration cytology and core biopsy in the preoperative diagnosis of screen-detected breast carcinoma. Br J Cancer 95(1):62–66PubMedCrossRef Lieske B, Ravichandran D, Wright D (2006) Role of fine-needle aspiration cytology and core biopsy in the preoperative diagnosis of screen-detected breast carcinoma. Br J Cancer 95(1):62–66PubMedCrossRef
37.
Zurück zum Zitat Meunier M, Clough K (2002) Fine needle aspiration cytology versus percutaneous biopsy of nonpalpable breast lesions. Eur J Radiol 42(1):10–16PubMedCrossRef Meunier M, Clough K (2002) Fine needle aspiration cytology versus percutaneous biopsy of nonpalpable breast lesions. Eur J Radiol 42(1):10–16PubMedCrossRef
38.
Zurück zum Zitat Vimpeli SM, Saarenmaa I, Huhtala H, Soimakallio S (2008) Large-core needle biopsy versus fine-needle aspiration biopsy in solid breast lesions: comparison of costs and diagnostic value. Acta Radiol 49(8):863–869PubMedCrossRef Vimpeli SM, Saarenmaa I, Huhtala H, Soimakallio S (2008) Large-core needle biopsy versus fine-needle aspiration biopsy in solid breast lesions: comparison of costs and diagnostic value. Acta Radiol 49(8):863–869PubMedCrossRef
Metadaten
Titel
Diagnostic values of GHSR DNA methylation pattern in breast cancer
verfasst von
Sandeep Kumar Botla
Amin Moghaddas Gholami
Mahdi Malekpour
Evgeny A. Moskalev
Mahdi Fallah
Pouria Jandaghi
Ali Aghajani
Irina S. Bondar
Ramesh Omranipour
Fatemeh Malekpour
Abbas Mohajeri
Azin Jahangiri Babadi
Özgür Sahin
Vladimir V. Bubnov
Hossein Najmabadi
Jörg D. Hoheisel
Yasser Riazalhosseini
Publikationsdatum
01.10.2012
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2197-z

Weitere Artikel der Ausgabe 3/2012

Breast Cancer Research and Treatment 3/2012 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.